Navigation Links
Soligenix Announces Collaboration with Infectious Disease Research Institute to Develop Thermostabilized Biodefense Vaccines Utilizing Novel Adjuvants
Date:6/27/2012

nal disorders characterized by severe inflammation, including acute radiation enteritis (SGX201), which is the subject of a recently completed National Cancer Institute (NCI)-supported Phase 1/2 clinical trial and pediatric Crohn's disease (SGX203).

Through its BioDefense Division, Soligenix is developing countermeasures pursuant to the Project BioShield Act of 2004. Soligenix's lead biodefense products in development are a recombinant subunit vaccine called RiVax™, which is designed to protect against the lethal effects of exposure to ricin toxin and VeloThrax™, a vaccine against anthrax exposure. RiVax™ has been shown to be well tolerated and immunogenic in a Phase 1 clinical trial in normal volunteers. Both RiVax™ and VeloThrax™ are currently the subject of a $9.4 million National Institute of Allergy and Infectious Disease (NIAID) grant supporting development of new thermostable vaccine technology known as ThermoVax™. Soligenix is also developing OrbeShield™ for the treatment of gastrointestinal acute radiation syndrome (GI ARS) and has demonstrated statistically significant preclinical survival results in a canine GI ARS model.

For further information regarding Soligenix, Inc., please visit the Company's website at www.soligenix.com.

This press release contains forward-looking statements that reflect Soligenix, Inc.'s current expectations about its future results, performance, prospects and opportunities. Statements that are not historical facts, such as "anticipates," "believes," "intends," or similar expressions, are forward-looking statements. These statements are subject to a number of risks, uncertainties and other factors that could cause actual events or results in future periods to differ materially from what is expressed in, or implied by, these statements. Soligenix cannot assure you that it will be able to successfully develop or commercialize pr
'/>"/>

SOURCE Soligenix, Inc.
Copyright©2012 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related biology technology :

1. Soligenix Reports Year-End 2011 Financial Results and Highlights Recent Accomplishments
2. Soligenix Announces 1 for 20 Reverse-Split of its Common Stock
3. Sequenom Announces Appointment of Carolyn Beaver to Chief Accounting Officer
4. Oil 4 Less LLC, the Home of Codatron TM Announces New Management Headquarters
5. United Therapeutics Announces Additional $100 Million Share Repurchase Program
6. Qualyst Transporter Solutions, LLC Announces Launch of New FDA Services Offering
7. Amarillo Biosciences Announces Plan to Open Asia Operations Center in Taipei, Taiwan
8. Bronstein, Gewirtz & Grossman, LLC Announces Investigation of American Oriental Bioengineering Inc.
9. Pacific BioStorage Announces an Exciting New First for The Life Sciences Industry in Southern California
10. JH Technologies Announces Launch of Their New Website
11. Cetero Research Announces Executive Appointments and New Company Name
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... Emerson Resources Inc. , a ... Signorino, the Company’s Chief Executive Officer and Chairman of ... years of service. As part of Emerson Resources’ planned ... been named as Dr. Signorino’s successor. , Dr. ... having made a significant contribution to the field during ...
(Date:5/21/2013)... 2013 Revolutionary Science, the manufacturer of ... announced today that they have expanded their colony counter ... IncuCount, IntelliCount, InCount and ImpressCount. These affordable colony ... useful in food microbiology and pharmaceutical manufacturing. , The ... A bright white enclosure with jet black accents ...
(Date:5/21/2013)... SoundConnect is pleased to announce the release ... in Canada. Lync is the next generation of ... and organizations to collaborate and communicate much more easily ... the United States. With the progressive rollout of Lync ... Canada, SoundConnect now offers a complete Microsoft Lync solution ...
(Date:5/20/2013)... 21, 2013 Grace Century , ... “game-changing” life science and health related private equity projects, ... its International Project Team. Dergham's expertise in finance and ... depth to Grace Century as it continues to look ... Ms. Dergham holds both an under graduate degree from ...
Breaking Biology Technology:Emerson Resources Announces CEO Retirement and Appointment of Successor 2Emerson Resources Announces CEO Retirement and Appointment of Successor 3Revolutionary Science Announces New Automatic and Manual Colony Counting Products 2SoundConnect Announces Microsoft Lync Release in Canada 2SoundConnect Announces Microsoft Lync Release in Canada 3Dalia Dergham Joins Grace Century FZ LLC International Project Team 2
... strain of virus broadens government readiness program -, ... the vaccines division of sanofi-aventis Group, announced,today that the ... H5N1 bulk vaccine antigen to produce approximately 38.5 million,doses ... avian influenza. Sanofi,Pasteur has a multi- year contract with ...
... CHINA, April 28 Simcere,Pharmaceutical Group (NYSE: ... generic pharmaceuticals and manufacturer of the patented,anti-cancer biotech ... has been,informed that one of its existing shareholders, ... beneficially owned by 15,individuals, including certain senior management ...
... 28 MBF Healthcare,Acquisition Corp. (Amex: MBH ... today that it and Critical Homecare,Solutions Holdings, Inc. ... therapy and specialty infusion services, are,scheduled to present ... Annual Deutsche,Bank Healthcare Conference in Boston, MA. On ...
Cached Biology Technology:U.S. Government Accepts $192 Million of sanofi pasteur H5N1 Bulk Vaccine Antigen for Pandemic Stockpile 2U.S. Government Accepts $192 Million of sanofi pasteur H5N1 Bulk Vaccine Antigen for Pandemic Stockpile 3U.S. Government Accepts $192 Million of sanofi pasteur H5N1 Bulk Vaccine Antigen for Pandemic Stockpile 4Simcere Pharmaceutical Group Reports Proposed Private Sale of Ordinary Shares by Existing Shareholder 2Simcere Pharmaceutical Group Reports Proposed Private Sale of Ordinary Shares by Existing Shareholder 3MBF Healthcare Acquisition Corp. and Critical Homecare Solutions Holdings, Inc. to Present at the 33rd Annual Deutsche Bank Healthcare Conference 2MBF Healthcare Acquisition Corp. and Critical Homecare Solutions Holdings, Inc. to Present at the 33rd Annual Deutsche Bank Healthcare Conference 3
(Date:5/19/2013)... Researchers have engineered a strain of electricity-producing bacteria that ... donor and carbon dioxide as its sole source of ... report their findings at the 113th General Meeting of ... first result of current production solely on hydrogen," says ... with his co-authors are part of the Lovley Lab ...
(Date:5/18/2013)... today at Digestive Disease Week (DDW) explores new discoveries ... of coffee on autoimmune disease and palliative care for ... been associated with reduced risk of fibrosis, a new ... java each month also correlate with lower risk for ... Clinic, Rochester, MN, linked coffee consumption with reduced risk ...
(Date:5/17/2013)... Bethesda, MD (May 18, 2013) The AGA Research ... research into the relationship between the gut microbiota, one ... health and disease. , The AGA Research Awards ... colleagues from Massachusetts General Hospital and Harvard Medical School, ... Award recipient. Dr. Chan will receive $25,000 of funding, ...
Breaking Biology News(10 mins):Coffee consumption associated with reduced risk of autoimmune liver disease 2New gut microbiome research to explore red meat -- colorectal cancer pathway 2
... Reportlinker.com announces that a new market research report is ... Markets: Microarrays and Lab-on-a-Chip http://www.reportlinker.com/p0170497/Global-Biochip-Markets-Microarrays-and-Lab-on-a-Chip.html ... STUDY GOALS AND OBJECTIVES BCC,s ... of current and emerging biochip technologies and products, and ...
... of Escherichia coli causing a severe illness called hemolytic-uremic syndrome ... killed more than 20 people and sickened more than 2,000. ... strain of E. coli O104:H4 that produces a ... E. coli O157:H7. Two isolates from this outbreak ...
... Ore. June 6, 2011. Sustainability is the theme for ... Society, scheduled to meet in Portland June 19 to ... others from academia, government, non-profit groups, and private industry ... products industry and share information about innovations in the ...
Cached Biology News:Reportlinker Adds Global Biochip Markets: Microarrays and Lab-on-a-Chip 2Reportlinker Adds Global Biochip Markets: Microarrays and Lab-on-a-Chip 3Reportlinker Adds Global Biochip Markets: Microarrays and Lab-on-a-Chip 4Reportlinker Adds Global Biochip Markets: Microarrays and Lab-on-a-Chip 5Reportlinker Adds Global Biochip Markets: Microarrays and Lab-on-a-Chip 6Reportlinker Adds Global Biochip Markets: Microarrays and Lab-on-a-Chip 7Reportlinker Adds Global Biochip Markets: Microarrays and Lab-on-a-Chip 8Reportlinker Adds Global Biochip Markets: Microarrays and Lab-on-a-Chip 9Reportlinker Adds Global Biochip Markets: Microarrays and Lab-on-a-Chip 10Reportlinker Adds Global Biochip Markets: Microarrays and Lab-on-a-Chip 11Reportlinker Adds Global Biochip Markets: Microarrays and Lab-on-a-Chip 12Reportlinker Adds Global Biochip Markets: Microarrays and Lab-on-a-Chip 13Reportlinker Adds Global Biochip Markets: Microarrays and Lab-on-a-Chip 14Reportlinker Adds Global Biochip Markets: Microarrays and Lab-on-a-Chip 15Two isolates from E. coli outbreak available 2
PFM8 Antibody...
Rabbit polyclonal to TRPM8 (rating: ****) ( Abpromise for all tested applications). entrezGeneID: 79054 SwissProtID: Q3YFM7...
Phospho- (Ser/Thr) PDK1 Docking Motif (18A2) Mouse mAb...
Component in MasterPure™ Purification Kits...
Biology Products: